×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IMRX – immuneering corporation - class a (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IMRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/23
08:00 am
imrx
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
Low
Report
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
12/20
01:30 am
imrx
Immuneering (NASDAQ:IMRX) was downgraded by analysts at Wall Street Zen<
Medium
Report
Immuneering (NASDAQ:IMRX) was downgraded by analysts at Wall Street Zen<
12/17
05:28 pm
imrx
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA [Yahoo! Finance]
Medium
Report
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA [Yahoo! Finance]
12/17
04:05 pm
imrx
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
Medium
Report
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
12/16
04:37 pm
imrx
Immuneering (NASDAQ:IMRX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Immuneering (NASDAQ:IMRX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/16
08:37 am
imrx
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]
Low
Report
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]
12/16
08:00 am
imrx
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
Medium
Report
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
12/15
09:31 am
imrx
Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO) [Yahoo! Finance]
Medium
Report
Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO) [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
04:05 pm
imrx
immuneering corporation - class a
MISS
Report
-0.3%
immuneering corporation - class a
8/13/2025
04:05 pm
imrx
immuneering corporation - class a
IN-LINE
Report
-3.8%
immuneering corporation - class a
5/5/2025
04:05 pm
imrx
immuneering corporation - class a
MISS
Report
-4.8%
immuneering corporation - class a
3/20/2025
04:05 pm
imrx
immuneering corporation - class a
MISS
Report
9.1%
immuneering corporation - class a
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
04:19 pm
imrx
Form 10-Q Immuneering Corp For: Sep 30
Low
Report
Form 10-Q Immuneering Corp For: Sep 30
11/12
04:09 pm
imrx
Form 8-K Immuneering Corp For: Nov 12
Low
Report
Form 8-K Immuneering Corp For: Nov 12
10/21
09:03 am
imrx
Form SCHEDULE 13G Immuneering Corp Filed by: Empery Asset Management, LP
Medium
Report
Form SCHEDULE 13G Immuneering Corp Filed by: Empery Asset Management, LP
10/7
03:50 pm
imrx
Form SCHEDULE 13G Immuneering Corp Filed by: FMR LLC
Low
Report
Form SCHEDULE 13G Immuneering Corp Filed by: FMR LLC
10/7
08:56 am
imrx
Form 4 Immuneering Corp For: Oct 03 Filed by: Feinberg Peter
Medium
Report
Form 4 Immuneering Corp For: Oct 03 Filed by: Feinberg Peter
10/3
04:16 pm
imrx
Form SCHEDULE 13G Immuneering Corp Filed by: HBM Healthcare Investments (Cayman) Ltd.
Low
Report
Form SCHEDULE 13G Immuneering Corp Filed by: HBM Healthcare Investments (Cayman) Ltd.
10/2
09:03 am
imrx
Form 4 Immuneering Corp For: Oct 01 Filed by: Morales Mallory
Low
Report
Form 4 Immuneering Corp For: Oct 01 Filed by: Morales Mallory
10/2
08:57 am
imrx
Form 4 Immuneering Corp For: Oct 01 Filed by: Neufeld Leah R
Low
Report
Form 4 Immuneering Corp For: Oct 01 Filed by: Neufeld Leah R
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: